Business
SNG: Egypt: Rameda reports 44.3% YoY consolidated profit decline in Q1 2025
SNG: Egypt: Rameda reports 44.3% YoY consolidated profit decline in Q1 2025
About this update from Tenth Of Ramadan Pharmaceutical Industries & Diagnostic-rameda
Staff WriterArab Finance: The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) posted a 44.26% year-on-year (YoY) leap in consolidated net profits attributable to the parent company in the first quarter (Q1) of 2025, achieving EGP 82.243 million from EGP 57.009 million, according to a statement.However, revenues jumped to EGP 865.616 million in the January-March period, up from EGP 456.233 million in the corresponding period a year ago.Rameda’s standalone net profits after tax rose to EGP 76.717 million in Q1 2025 from EGP 53.539 million in Q1 2024.Rameda is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals. It operates three fully independent factories at its plant, including 20 production lines capable of producing a wide range of general medicinal forms, namely eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials, among others.© 2020-2023 Arab Finance For Information Technology. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info).Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.